The need for new anti-infectives (bacterial, fungal and viral) could never be greater — COVID-19 should be a warning of how quickly the world can be caught off guard. However, while COVID-19 has captured the world's attention for now, and rightfully so, there is another pandemic that has been smoldering beneath the surface; drug resistant bacteria and fungi driving alarming rates of invasive disease which result in high rates of mortality and a significant burden on the healthcare system. The lag in development of novel anti-infectives is multi-factorial, but as we move through 2020 and beyond, there is indeed a renaissance in drug development taking place that has not been observed for some time. This includes novel drugs and new drug classes, changes in regulatory guidelines and incentives for drug developers, changes to clinical trial design and execution, changes in views from payers and the investment community. Please join us as we hear from four panels of companies in various stages of development, from early stage to near commercialization, that represent the next wave of innovation in the infectious disease sector.